Dual Chamber Injection Device Market to Reach $5.3 Billion by 2024

AMHERST, N.H., November 30, 2017 (Newswire.com) - The need to reconstitute lyophilized drugs at the point of administration and the potential safety and compliance issues this represents for patients have led to increasing interest in injection devices that can eliminate the number of steps required to convert the drug powder to liquid form and make it available for injection. Dual chamber syringes and injectors – devices that allow reconstitution to take place within the device immediately prior to injection - are the most elegant engineering solution to this need. As more drug developers move toward these devices, the value of dual chamber-delivered drug therapeutics will reach $5.3 billion annually by 2024.

The inherent instability of important drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are administered. Liquid protein drugs require refrigeration until dispensed – a distribution strategy referred to as the "Cold Chain." Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to administration.

While the majority of dual chamber injection devices in currently marketed drug-device products are custom implementations a few companies, most notably Ypsomed and Vetter, offer standard dual chamber device platform solutions for drug developers. This strategy typically reduces development costs and time-to-market at the possible expense of creating a somewhat less-than-unique product look and feel from a branding perspective. Suppliers of dual chamber drug cartridges, which are designed to fit within a pen injector body, operate either on a traditional OEM outsource contract basis, or in the case of vertically integrated device suppliers, as turnkey cartridge-and-device solution suppliers.

In terms of market penetration, dual chamber injection devices have a significant presence in seven major therapeutic segments. We expect this number to grow as the influence of environmentally sensitive drugs on therapeutic patient care increases.

These findings are contained in a new and comprehensive report researched and written by Greystone Research Associates. Dual Chamber Syringes & Injectors to 2024: Devices, Therapeutics, Markets, Players and Forecasts includes detailed analysis of dual chamber devices, an analysis of dual chamber device markets, assessments of dual chamber device/drug products and profiles of market participants.

More information is available at www.greystoneassociates.org.

About Greystone

Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.

Contact:

Mark Smith
​Voice: 603-595-4340
​Fax: 603-218-7020
​mks@greystoneassociates.org
​www.greystoneassociates.org                                    

Source: Greystone Research Associates